Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11935691 | 0.76 | ALDH1A1 (0.46) | ALDH1A1MAPTTSHRCYP1A2RAB9A | |
| SCHEMBL19547053 | 0.75 | USP2 (0.52) | ALDH1A1MAPTTSHRCYP1A2SMN1; SMN2 | |
| SCHEMBL11935685 | 0.73 | KDM1A (0.46) | ALDH1A1MAPTTSHRRAB9ASMN1; SMN2 | |
| SCHEMBL7577389 | 0.72 | ALDH1A1 (0.53) | ALDH1A1MAPTTSHRCYP1A2RAB9A | |
| SCHEMBL12568146 | 0.71 | USP2 (0.57) | ALDH1A1MAPTTSHRCYP1A2RAB9A | |
| SCHEMBL23673311 | 0.71 | USP2 (0.47) | ALDH1A1MAPTTSHRCYP1A2SMN1; SMN2 | |
| SCHEMBL78225 | 0.70 | ALDH1A1 (0.51) | ALDH1A1MAPTCYP1A2RAB9ASMN1; SMN2 | |
| SCHEMBL13565847 | 0.70 | PKM (0.44) | ALDH1A1TSHRSMN1; SMN2HPGDNPC1 | |
| SCHEMBL13566034 | 0.70 | PKM (0.44) | ALDH1A1TSHRRAB9ASMN1; SMN2HPGD | |
| SCHEMBL17318090 | 0.69 | LMNA (0.48) | ALDH1A1MAPTTSHRRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303138-A1 | Combination Therapy Of Substituted Oxazolidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20150166568-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-8822458-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20130316999-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-28 | — | — | US | disclosed |
| US-8530505-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| US-20130005701-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| US-8129378-B2 | Rivaroxaban and derivatives, synthesis; atherosclerosis; arthritis; Alzheimer's disease or cancer | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20100267685-A1 | Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-21 | — | — | US | disclosed |
| US-7767702-B2 | Combinations of oxazolidinones such as rivaroxaban with a platelet aggregation inhibitor such as a clopidogrel for the prophylaxis and/or treatment of thromboembolic disorders | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20100160301-A1 | MICROANGIOPATHY TREATMENT AND PREVENTION | BAYER HEALTHCARE AG | 2010-06-24 | — | — | US | disclosed |
| US-7592339-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7585860-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-09-08 | — | — | US | disclosed |
| US-7576111-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER SCHERING PHARMA AG (DE) | 2009-08-18 | — | — | US | disclosed |
| US-20080306070-A1 | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders | BAYER HEALTHCARE AG | 2008-12-11 | — | — | US | disclosed |
| US-20080200674-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20080090815-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-7157456-B2 | Anticoagulates for treating cardiovascular disorders, such as myocardial infarct, angina pectoris, restenoses after angioplasty, bypass, stroke; treatment of atherosclerosis, arthritis, Alzheimer's disease or cancer | BAYER HEALTHCARE AG (DE) | 2007-01-02 | — | — | US | disclosed |
| US-20060258724-A1 | Substituted Oxazolidinones and Their Use in the Field of Blood Coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-16 | — | — | US | disclosed |
| US-20040242660-A1 | Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| US-20030153610-A1 | Substituted oxazolidinones and their in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090815-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | ALDH1A1 194/4885MAPT 4752/4885TSHR 3772/4885 |
| US-20160303138-A1 | Combination Therapy Of Substituted Oxazolidinones | P2RY12, P2RY11, P2RY1 | ALDH1A1 153/4885MAPT 4859/4885TSHR 2864/4885 |
| US-20130005701-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | ALDH1A1 194/4885MAPT 4752/4885TSHR 3772/4885 |
| US-20130316999-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | ALDH1A1 194/4885MAPT 4752/4885TSHR 3772/4885 |
| US-20080306070-A1 | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders | OTC, SDHA, SDHB | ALDH1A1 358/4885MAPT 2890/4885TSHR 3752/4885 |
| US-20040242660-A1 | Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders | SERPINC1, XDH, SDHB | ALDH1A1 237/4885MAPT 4709/4885TSHR 4106/4885 |
| US-20080200674-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | ALDH1A1 194/4885MAPT 4752/4885TSHR 3772/4885 |
| US-20100267685-A1 | Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones | SERPINC1, SDHB, F2 | ALDH1A1 393/4885MAPT 4779/4885TSHR 3562/4885 |
| US-20030153610-A1 | Substituted oxazolidinones and their in the field of blood coagulation | F2, F11, SERPINC1 | ALDH1A1 96/4885MAPT 4763/4885TSHR 4123/4885 |
| US-20100160301-A1 | MICROANGIOPATHY TREATMENT AND PREVENTION | SERPINC1, TFPI, F11 | ALDH1A1 957/4885MAPT 3388/4885TSHR 3757/4885 |
| US-20150166568-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | ALDH1A1 194/4885MAPT 4752/4885TSHR 3772/4885 |
| US-20060258724-A1 | Substituted Oxazolidinones and Their Use in the Field of Blood Coagulation | F2, F11, F13B | ALDH1A1 194/4885MAPT 4752/4885TSHR 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.